Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Ensaio para avaliar a segurança e eficácia do suporte circulatório mecânico em pacientes com insuficiência cardíaca avançada (TEAM-HF)

3 de novembro de 2026 atualizado por: Abbott Medical Devices

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

Visão geral do estudo

Descrição detalhada

Patients with heart failure (HF) suffer from a high degree of morbidity and mortality. Left ventricular assist device (LVAD) therapy has become the standard of care for the treatment of advanced HF patients who are deemed to be dependent on continuous intravenous inotropes, extending life expectancy, enhancing overall quality of life, and improving functional capacity. However, use of LVADs in ambulatory, non-inotrope dependent advanced HF population is limited. Elevated mean pulmonary artery pressure (PAP) secondary to left ventricular failure has emerged as a potential predictor of increased mortality risk for patients refractory to maximally tolerated guideline directed medical therapy (GDMT). In these patients, left ventricular failure with elevated mean PAP may represent objective criteria to identify advanced HF patients requiring heart replacement therapies such as LVAD.

The TEAM-HF IDE trial will enroll approximately 850 subjects with New York Heart Association (NYHA) Class IIIB/IV HF who had a prior heart failure hospitalization and an elevated mean PAP secondary to left ventricular failure. Elevated mean PAP will be identified using an implanted PAP monitoring sensor, the CardioMEMS PA Sensor. All subjects enrolled can have a previously implanted CardioMEMS PA Sensor or, if not, will be implanted with the CardioMEMS PA Sensor after enrollment. The overall objectives of TEAM-HF trial are two-fold: 1) To determine whether PAP can objectively identify patients most at risk for worsening HF and therefore most likely to benefit from earlier intervention with LVAD therapy and 2) To determine the benefit of LVAD therapy in non-inotrope advanced HF patients with elevated mean PAP refractory to GDMT.

The trial will include approximately 75 global sites and consists of a Randomized Arm and a Single Arm Registry.

The TEAM-HF Randomized Arm is a prospective, randomized, open-label study of the HeartMate 3 (HM3) left ventricular assist system (LVAS) versus continued GDMT in non-inotrope dependent HF patients. The objectives of the Randomized Arm are 1) To establish an objective disease-state criteria to trigger referral for a HM3 LVAS and 2) Demonstrate improvement in survival when non-inotrope dependent advanced HF patients are treated with the HM3 LVAS compared to being managed on medical therapy alone.

The TEAM-HF Single Arm Registry is a prospective, single-arm, open-label study of non-inotrope dependent HF patients who do not meet a mean PAP threshold after GDMT optimization. The objective of the Single Arm Registry is to characterize the progression of patients with non-inotrope dependent HF without elevated PAP.

Tipo de estudo

Intervencional

Inscrição (Estimado)

850

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Saxon
      • Hanover, Saxon, Alemanha, 30625
        • Recrutamento
        • Medizinische Hochschule Hannover
        • Investigador principal:
          • Dominik Berliner, MD
        • Contato:
    • Saxony
      • Leipzig, Saxony, Alemanha, 04289
    • State of Berlin
      • Berlin, State of Berlin, Alemanha, 13353
        • Recrutamento
        • Deutsches Herzzentrum der Charité
        • Investigador principal:
          • Felix Schoenrath, MD
        • Contato:
    • Riyadh Region
      • Riyadh, Riyadh Region, Arábia Saudita, 11525
        • Recrutamento
        • King Fahad Medical City
        • Investigador principal:
          • Mohammed Alreshidan, MD
        • Contato:
      • Riyadh, Riyadh Region, Arábia Saudita, 12713
        • Recrutamento
        • King Faisal Specialist Hospital
        • Contato:
        • Investigador principal:
          • Jehad Abdulhamid Al Buraiki, MD
    • Copenhagen
      • Copenhagen, Copenhagen, Dinamarca, 2100
        • Recrutamento
        • Rigshospitalet
        • Contato:
        • Investigador principal:
          • Kasper Rossing, MD
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85006
        • Retirado
        • Banner-University Medical Center Phoenix
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • Recrutamento
        • Baptist Health Medical Center
        • Investigador principal:
          • Patrick Campbell, MD
        • Contato:
    • California
      • Sacramento, California, Estados Unidos, 95816
        • Recrutamento
        • Sutter Medical Center
        • Contato:
        • Investigador principal:
          • Michael Gibson, MD
      • San Francisco, California, Estados Unidos, 94143
        • Recrutamento
        • University of California at San Francisco
        • Contato:
        • Investigador principal:
          • Shweta Motiwala, MD
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20010
        • Recrutamento
        • Washington Hospital Center
        • Investigador principal:
          • Sheikh Farooq, MD
        • Contato:
    • Florida
      • Gainesville, Florida, Estados Unidos, 32610
        • Recrutamento
        • Shands at the University of Florida
        • Investigador principal:
          • Mustafa Ahmed, MD
        • Contato:
      • Weston, Florida, Estados Unidos, 33331
        • Recrutamento
        • Cleveland Clinic Florida
        • Contato:
          • Maria Mejia-Gomez
          • Número de telefone: 954-659-5888
          • E-mail: mejiagm@ccf.org
        • Investigador principal:
          • Mauricio Velez, MD
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30309
        • Recrutamento
        • Piedmont Heart Institute
        • Investigador principal:
          • Catherine Marti, MD
        • Contato:
      • Augusta, Georgia, Estados Unidos, 30901
        • Recrutamento
        • Piedmont Augusta Hospital
        • Investigador principal:
          • Darshak Karia, MD
        • Contato:
      • Marietta, Georgia, Estados Unidos, 30060
        • Recrutamento
        • WellStar Kennestone Hospital
        • Investigador principal:
          • Abdul Bikak, MD
        • Contato:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Recrutamento
        • University of Chicago
        • Contato:
        • Investigador principal:
          • Nikhil Narang, MD
      • Oakbrook Terrace, Illinois, Estados Unidos, 60181
        • Recrutamento
        • Advocate Health & Hospitals Corporation
        • Contato:
        • Investigador principal:
          • Vinh Chau, MD
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46240
        • Recrutamento
        • St. Vincent Hospital
        • Investigador principal:
          • Ashwin Ravichandran, MD
        • Contato:
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
        • Recrutamento
        • University of Iowa Hospitals & Clinics
        • Contato:
        • Investigador principal:
          • Anthony Panos, MD
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Recrutamento
        • Kansas University Medical Center
        • Contato:
        • Investigador principal:
          • Zubair Shah, MD
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40536
        • Rescindido
        • University of Kentucky
      • Louisville, Kentucky, Estados Unidos, 40202
        • Recrutamento
        • Norton Hospital
        • Contato:
        • Investigador principal:
          • Alkhalil Bassel, MD
    • Maine
      • Portland, Maine, Estados Unidos, 04102
        • Recrutamento
        • Maine Medical Center
        • Contato:
        • Investigador principal:
          • Peter Kennel, MD
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Recrutamento
        • Massachusetts General Hospital
        • Contato:
        • Investigador principal:
          • Erin Coglianese, MD
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48202
        • Recrutamento
        • Henry Ford Hospital
        • Contato:
        • Investigador principal:
          • Lindsey Aurora, MD
      • Grand Rapids, Michigan, Estados Unidos, 49503
        • Recrutamento
        • Spectrum Health Butterworth Hospital
        • Contato:
        • Investigador principal:
          • Matthew Gonzalez, MD
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55407
        • Recrutamento
        • Minneapolis Heart Institute
        • Investigador principal:
          • Mosi Bennett, MD
        • Contato:
      • Rochester, Minnesota, Estados Unidos, 55905
        • Recrutamento
        • Mayo Clinic
        • Contato:
        • Investigador principal:
          • Andrew Rosenbaum, MD
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64111
        • Recrutamento
        • St. Luke's Hospital
        • Investigador principal:
          • Timothy Fendler, MD
        • Contato:
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68198
        • Recrutamento
        • University of Nebraska Medical Center
        • Contato:
        • Investigador principal:
          • Adam Burdorf, DO
    • New Jersey
      • Hackensack, New Jersey, Estados Unidos, 07601
        • Recrutamento
        • Hackensack University Medical Center
        • Investigador principal:
          • Kanika Mody, MD
        • Contato:
      • Newark, New Jersey, Estados Unidos, 07112
        • Recrutamento
        • Newark Beth Israel Medical Center
        • Investigador principal:
          • Igor Gosev, MD
        • Contato:
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87102
        • Recrutamento
        • New Mexico Heart Institute
        • Contato:
        • Investigador principal:
          • Dana Booth, MD
    • New York
      • Manhasset, New York, Estados Unidos, 11030
        • Recrutamento
        • North Shore University Hospital
        • Contato:
        • Investigador principal:
          • Maria Avila, MD
      • New York, New York, Estados Unidos, 10032
        • Recrutamento
        • New York-Presbyterian/Columbia University Medical Center
        • Contato:
        • Investigador principal:
          • Dor Lotan, MD
      • Rochester, New York, Estados Unidos, 14642
        • Recrutamento
        • University of Rochester Medical Center
        • Contato:
        • Investigador principal:
          • Leway Chen, MD
      • The Bronx, New York, Estados Unidos, 10467
        • Recrutamento
        • Montefiore Medical Center - Moses Campus
        • Investigador principal:
          • Yogita Rochlani, MD
        • Contato:
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • Recrutamento
        • University of North Carolina at Chapel Hill
        • Contato:
        • Investigador principal:
          • William Mostertz, MD
      • Charlotte, North Carolina, Estados Unidos, 28203
        • Recrutamento
        • Carolinas Medical Center
        • Contato:
        • Investigador principal:
          • Joseph Mishkin, MD
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
      • Cleveland, Ohio, Estados Unidos, 44195
        • Recrutamento
        • The Cleveland Clinic Foundation
        • Contato:
          • Barbara Gus
          • Número de telefone: 216-445-6552
          • E-mail: gusb@ccf.org
        • Investigador principal:
          • Michael Tong, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73112
        • Recrutamento
        • Integris Baptist Medical Center
        • Contato:
        • Investigador principal:
          • Luke Cunningham, MD
      • Tulsa, Oklahoma, Estados Unidos, 74104
        • Recrutamento
        • Oklahoma Heart Institute at Utica
        • Contato:
        • Investigador principal:
          • Luis David Meggo Quiroz, MD
      • Tulsa, Oklahoma, Estados Unidos, 74136
        • Recrutamento
        • Saint Francis Hospital
        • Investigador principal:
          • Douglas Ensley, MD
        • Contato:
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239
        • Recrutamento
        • Oregon Health & Science University
        • Investigador principal:
          • Johannes Steiner, MD
        • Contato:
    • Pennsylvania
      • Abington, Pennsylvania, Estados Unidos, 19001
        • Recrutamento
        • Abington Memorial Hospital
        • Contato:
        • Investigador principal:
          • Alexander Shpilman, MD
      • Hershey, Pennsylvania, Estados Unidos, 17033
        • Recrutamento
        • Penn State Milton S. Hershey Medical Center
        • Investigador principal:
          • John Boehmer, MD
        • Contato:
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Recrutamento
        • University of Pennsylvania
        • Contato:
        • Investigador principal:
          • Himabindu Vidula, MD
      • Philadelphia, Pennsylvania, Estados Unidos, 15213
        • Recrutamento
        • University of Pittsburgh Medical Center (UPMC)
        • Investigador principal:
          • Gavin Hickey, MD
        • Contato:
      • Pittsburgh, Pennsylvania, Estados Unidos, 15212
        • Recrutamento
        • Allegheny General Hospital
        • Investigador principal:
          • Matthew Lander, MD
        • Contato:
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Recrutamento
        • Medical University of South Carolina
        • Investigador principal:
          • Arman Kilic, MD
        • Contato:
      • Columbia, South Carolina, Estados Unidos, 29203
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38120
        • Recrutamento
        • The Stern Cardiovascular Foundation
        • Contato:
        • Investigador principal:
          • Todd Edwards, MD
    • Texas
      • Austin, Texas, Estados Unidos, 78705
        • Recrutamento
        • Ascension Texas Cardiovascular
        • Contato:
        • Investigador principal:
          • Raymond Bietry, MD
      • Dallas, Texas, Estados Unidos, 75246
        • Recrutamento
        • Baylor University Hospital
        • Contato:
        • Investigador principal:
          • Cesar Guerrero-Miranda, MD
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Houston Methodist
        • Contato:
        • Investigador principal:
          • Cindy Martin, MD
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • CHI St. Luke's Health Baylor College of Medicine Medical Center
        • Investigador principal:
          • Ajith Nair, MD
        • Contato:
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • UTHealth Memorial Hermann
        • Contato:
        • Investigador principal:
          • Nathan Sriram, MD
      • Plano, Texas, Estados Unidos, 75093
        • Recrutamento
        • The Heart Hospital Baylor Plano
        • Contato:
        • Investigador principal:
          • Aasim Afzal, MD
      • Temple, Texas, Estados Unidos, 76508
        • Recrutamento
        • Scott & White Memorial Hospital
        • Contato:
        • Investigador principal:
          • Yevgeniy Khariton, MD
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84132
        • Recrutamento
        • University of Utah Hospital
        • Investigador principal:
          • Craig Selzman, MD
        • Contato:
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • Recrutamento
        • University of Virginia Medical Center
        • Contato:
        • Investigador principal:
          • Mirnela Byku, MD
      • Richmond, Virginia, Estados Unidos, 23219
        • Recrutamento
        • Virginia Commonwealth University
        • Investigador principal:
          • Keyur Shah, MD
        • Contato:
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53215
        • Recrutamento
        • Aurora Medical Group
        • Investigador principal:
          • Nasir Sulemanjee, MD
        • Contato:
    • Holland
      • Rotterdam, Holland, Holanda, 3015 CE
        • Recrutamento
        • Erasmus MC - Thoraxcenter
        • Contato:
        • Investigador principal:
          • Rudolf De Boer, MD
    • Utrecht
      • Utrecht, Utrecht, Holanda, 3584 CX
        • Recrutamento
        • UMC Utrecht
        • Investigador principal:
          • Linda Van Laake, MD
        • Contato:
    • Piedmont
      • Turin, Piedmont, Itália, 10126
        • Recrutamento
        • A.O.U. Citta della Salute e della Scienza di Torino
        • Contato:
        • Investigador principal:
          • Antonino Loforte, MD
    • CBohmia
      • Prague, CBohmia, Tcheca, 14021
        • Recrutamento
        • IKEM Prague
        • Investigador principal:
          • Ivan Netuka, MD
        • Contato:
    • State of Vienna
      • Vienna, State of Vienna, Áustria, 1090
        • Recrutamento
        • AKH -Wien
        • Contato:
        • Investigador principal:
          • Daniel Zimpfer, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure
  2. LVEF ≤30% and Cardiac Index ≤ 2.5 L/min/m²
  3. Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL/kg/min (or <50% of predicted peak VO2 value)
  4. NYHA Class IIIB or NYHA Class IV
  5. Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months
  6. Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant
  7. Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group

Randomization Criteria:

  1. Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days.
  2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
  3. mean PAP ≥ 30 mmHg.
  4. The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant.

Single Arm Registry Criteria:

  1. Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial.
  2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
  3. mean PAP <30 mmHg

Exclusion Criteria:

  1. Subject is < 18 years of age at the time of informed consent.

  2. Dependent on IV inotrope in the last 30 days.

  3. Contra-indications to HM3 LVAS or CardioMEMS HF system.

  4. Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy.

  5. Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter.

  6. Existence of ongoing MCS.

  7. Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant.

  8. History of any solid organ transplant.

  9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management.

  10. Presence of an active, uncontrolled infection.

  11. Complex congenital heart disease.

  12. Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD.

  13. History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (>1 episode) pulmonary embolism and/or deep vein thrombosis.

  14. Planned VAD or Bi-VAD support prior to enrollment.

  15. Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure:

    1. An INR ≥ 2.0 not due to anticoagulation therapy
    2. An eGFR < 30 mL/min/1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis.
    3. Biopsy proven liver cirrhosis.
    4. Need for chronic renal replacement therapy.
    5. History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 < 30% predicted.
    6. History of cerebrovascular disease with significant (> 80%) uncorrected internal carotid stenosis.
    7. Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration.
  16. Any condition other than HF that could limit survival to less than 24 months.

  17. Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Randomized Arm - HM3 Group

Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the HM3 group will receive the device within 14 days of randomization.

The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Outros nomes:
  • CardioMEMS
  • Sensor CardioMEMS PA

The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.

Outros nomes:
  • HM3

Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Outros nomes:
  • GDMT
Experimental: Randomized Arm - Control Group

Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the control group will continue their medical therapy per established heart failure guidelines.

The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Outros nomes:
  • CardioMEMS
  • Sensor CardioMEMS PA

Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Outros nomes:
  • GDMT
Experimental: Single Arm Registry

Patients who do not meet the mean PAP threshold (mean PAP <30 mmHg) and are enrolled in the single arm will continue their medical therapy per established heart failure guidelines.

The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Outros nomes:
  • CardioMEMS
  • Sensor CardioMEMS PA

Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Outros nomes:
  • GDMT

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Survival at 2 years free of disabling stroke, reoperation to replace the device, or worsening HF requiring listing for urgent heart transplantation or mechanical circulatory support, enrollment into hospice, or dependence on IV inotropes
Prazo: 2 years

The powered primary endpoint will be analyzed at 2 years following the Com-Nougue method and will be compared between the HM3 Group (HM3 LVAD) and the Control Group (GDMT) within the Intention-to-treat (ITT) population.

2 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Rate of Safety Outcomes at 1-year
Prazo: 1 year

The powered secondary endpoint of Rate of Safety Outcomes at 1-year will be evaluated within the Intention-to-treat (ITT) population against a pre-specified performance goal.

Components consist of the following:

  1. Heart failure hospitalization

  2. Major Adverse Event (MAE) including:

    • Stroke
    • Non-surgical bleeding (>14 days post implant) requiring hospitalization
    • Renal failure requiring hospitalization
    • Driveline infection requiring hospitalization
1 year
Survival at 2 years
Prazo: 2 years

The powered secondary endpoint of survival at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population.

2 years
Quality of life score assessed with the Kansas City Cardiomyopathy Questionnaire
Prazo: 2 years

The secondary endpoint of Quality-of-life score at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Quality of life at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

The KCCQ scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Improvement of KCCQ by at least 10 points is considered clinically significant.

2 years
Six-minute walk distance
Prazo: 2 years

The secondary endpoint of six-minute walk distance at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of six-minute walk distance at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
Hospitalizations for HF and/or Urgent HF Visit
Prazo: 2 years

The secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
Days alive and outside of the hospital
Prazo: 2 years

The secondary endpoint of days alive and outside of the hospital at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of days alive and outside of the hospital at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
All-cause hospitalizations
Prazo: 2 years

The secondary endpoint of all-cause hospitalizations at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all-cause hospitalizations at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
All adverse events (including all strokes) regardless of severity
Prazo: 2 years

The secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Finkelstein-Schoenfeld Win Ratio
Prazo: 5 years

The Finkelstein-Schoenfeld Win Ratio will be explored at 5 years as an additional analysis with the following hierarchy:

  1. Survival
  2. Days alive outside of the hospital
  3. Quality of Life assessed with the KCCQ (considered a tie if within 10 points)
  4. Functional Capacity (Six-minute walk distance)

The Finkelstein-Schoenfeld Win Ratio will be analyzed between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the Finkelstein-Schoenfeld Win Ratio will be descriptively analyzed between the Single Arm and both the HM3 Group and Control Group of the Randomized Arm separately.

5 years
Survival free of urgent LVAD or transplant
Prazo: 5 years

This additional descriptive analysis at 5-years will be performed to evaluate the proportion of patients who are alive and free of device replacement or transplant in the HM3 Group compared to the Single Arm Registry (de novo implant or transplant)

5 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Kelly O'Connell, PhD, Abbott

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

13 de dezembro de 2024

Conclusão Primária (Estimado)

1 de setembro de 2029

Conclusão do estudo (Estimado)

1 de setembro de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

24 de julho de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

24 de julho de 2024

Primeira postagem (Real)

29 de julho de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever